NOVOCURE LIMITED

(NVCR)
  Reporte
Tiempo real estimado Cboe BZX  -  17:46 15/08/2022
84.62 USD   -1.52%
29/07NOVOCURE LIMITED : Truist Securities mantiene una recomendación de compra.
MM
29/07NOVOCURE LIMITED : Recibe una recomendación de compra del Piper Sandler
MM
28/07Las pérdidas del segundo trimestre de NovoCure se amplían, los ingresos netos aumentan
MT
ResumenCotizacionesGráficosNoticiasRatingsAgendaEmpresaFinanzasConsensoRevisionesDerivados 
ResumenTodasRecomendaciones analistasOtros idiomasComunicadosPubls. oficialesNoticias del sector
Noticias en otros idiomas sobre NOVOCURE LIMITED
10/08Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
04/08INSIDER SELL : Novocure
28/07NovoCure Q2 Loss Widens, Net Revenue Rises
28/07TRANSCRIPT : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
28/07NOVOCURE : Q2 Earnings Snapshot
28/07NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
28/07Novocure Reports Second Quarter 2022 Financial Results
28/07NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
28/07NovoCure Limited Reports Earnings Results for the Second Quarter and Six Months Ended J..
28/07Earnings Flash (NVCR) NOVOCURE Reports Q2 Loss $-0.23
28/07Earnings Flash (NVCR) NOVOCURE Reports Q2 Revenue $140.9M
27/07Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fie..
11/07Wedbush Sees Continued Modest Growth in NovoCure's Optune Franchise
01/07Novocure to Report Second Quarter 2022 Financial Results
24/06NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
24/06NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
21/06NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination ..
21/06Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
21/06Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
10/06NOVOCURE LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. o..
03/06Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results
03/06Zai Lab, Novocure's Phase 2 Study of Gastric Cancer Combination Therapy Meets Primary E..
03/06NOVOCURE : Press Release of NovoCure Limited, dated June 3, 2022 - Form 8-K
03/06NOVOCURE LTD : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
03/06Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Field..
03/06Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Field..
26/05SECTOR UPDATE : Health Care Stocks Propelled Higher Near Thursday Close
26/05SECTOR UPDATE : Health Care Stocks Edging Higher on Thursday
26/05NOVOCURE : Announces Clinical Collaboration with MSD on a Registrational-Intent Study to E..
26/05NovoCure Teams Up With Merck to Study Tumor Treating Fields Combined With Keytruda to T..
26/05NOVOCURE LTD : Entry into a Material Definitive Agreement, Other Events, Financial Stateme..
26/05Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to ..
26/05NovoCure Limited Announces Clinical Collaboration with MSD on a Registrational-Intent S..
16/05NovoCure's Shares Rise After HC Wainwright Initiates Coverage at Buy
28/04NovoCure's Q1 Net Loss Flat, Revenue Rises
28/04TRANSCRIPT : NovoCure Limited, Q1 2022 Earnings Call, Apr 28, 2022
28/04NOVOCURE : Q1 Earnings Snapshot
28/04NOVOCURE : Quarterly net revenues of $137.5 million with 80% gross margin - Form 8-K
28/04Earnings Flash (NVCR) NOVOCURE Reports Q1 Loss $-0.04, vs. Street Est of $-0.19
28/04Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $137.5M, vs. Street Est of $134.3M
28/04NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
28/04Novocure Reports First Quarter 2022 Financial Results
28/04NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2022
19/04Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
13/04NOVOCURE LTD : Change in Directors or Principal Officers, Financial Statements and Exhibit..
13/04Novocure Limited Announces Resignation of Sherilyn McCoy from the Board of Directors
08/04Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) ..
07/04NOVOCURE LTD : Other Events, Financial Statements and Exhibits (form 8-K)
01/04Novocure to Report First Quarter 2022 Financial Results
24/03Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survi..
24/03NovoCure Limited Announces Updated 2-THE-TOP Data Suggest Improvements in Progression-F..
23/03Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 ..
23/03NOVOCURE LTD : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
23/03NovoCure's Phase 3 Study of Tumor Treating Fields Given Independent Recommendation to C..
23/03NOVOCURE : Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 S..
23/03Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 ..
09/03INSIDER SELL : NovoCure
09/03INSIDER SELL : NovoCure
09/03INSIDER SELL : Novocure
28/02Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technologic..
24/02Novocure's General Counsel Resigns After 10 Years of Service
24/02Novocure Announces Resignation of Todd Longsworth as General Counsel
24/02TRANSCRIPT : NovoCure Limited, Q4 2021 Earnings Call, Feb 24, 2022
24/02NovoCure Swings to Loss, Revenue Declines in Q4; Shares Fall in Premarket
24/02NOVOCURE : Q4 Earnings Snapshot
24/02NOVOCURE : Invested record $201 million in 2021 in research and development initiatives in..
24/02New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
24/02Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Compa..
24/02Novocure Announces New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor..
24/02Earnings Flash (NVCR) NOVOCURE Posts Q4 Revenue $133.2M
24/02NOVOCURE LTD MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
24/02NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 202..
24/02NovoCure Limited Reports Earnings Results for the Full Year Ended December 31, 2021
08/02NovoCure Shares Rise After Loop Capital Initiates Coverage With Buy Rating, $200 Price ..
02/02NovoCure Shares Higher After Oppenheimer Upgrade to Outperform
1  2  3  4  5  6  7  8  9Siguiente
Próximo evento sobre NOVOCURE LIMITED